Impella 5.0 is associated with a reduction in vasoactive support and improves hemodynamics in cardiogenic shock: A single-center experience.
Michael J BashlineZachary RhinehartOlivia KolaJeffrey FowlerDavid KaczorowskiGavin HickeyPublished in: The International journal of artificial organs (2022)
Impella 5.0 is associated with a significant reduction in MCES and VIS scores in patients presenting with CS with 30-day survival being dependent on MCES.